Dataset Information

High-resolution gridded population datasets for Latin America and the Caribbean in 2010, 2015, and 2020.

ABSTRACT: The Latin America and the Caribbean region is one of the most urbanized regions in the world, with a total population of around 630 million that is expected to increase by 25% by 2050. In this context, detailed and contemporary datasets accurately describing the distribution of residential population in the region are required for measuring the impacts of population growth, monitoring changes, supporting environmental and health applications, and planning interventions. To support these needs, an open access archive of high-resolution gridded population datasets was created through disaggregation of the most recent official population count data available for 28 countries located in the region. These datasets are described here along with the approach and methods used to create and validate them. For each country, population distribution datasets, having a resolution of 3 arc seconds (approximately 100?m at the equator), were produced for the population count year, as well as for 2010, 2015, and 2020. All these products are available both through the WorldPop Project website and the WorldPop Dataverse Repository.

SUBMITTER: Sorichetta A

PROVIDER: S-EPMC4555876 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

High-resolution gridded population datasets for Latin America and the Caribbean in 2010, 2015, and 2020.

Sorichetta Alessandro A Hornby Graeme M GM Stevens Forrest R FR Gaughan Andrea E AE Linard Catherine C Tatem Andrew J AJ

Scientific data 20150901

The Latin America and the Caribbean region is one of the most urbanized regions in the world, with a total population of around 630 million that is expected to increase by 25% by 2050. In this context, detailed and contemporary datasets accurately describing the distribution of residential population in the region are required for measuring the impacts of population growth, monitoring changes, supporting environmental and health applications, and planning interventions. To support these needs, a ...[more]

PMID: 26347245

Similar Datasets

Project description:ObjectiveThere are limited published data about the circulation of influenza B/Victoria and B/Yamagata in Latin America and the Caribbean (LAC) and most countries have a vaccine policy that includes the use of the trivalent influenza vaccine. We analyzed influenza surveillance data to inform decision-making in LAC about prevention strategies, such as the use of the quadrivalent influenza vaccine.MethodsThere are a total of 28 reference laboratories and National Influenza Centers in LAC that conduct influenza virologic surveillance according to global standards, and on a weekly basis upload their surveillance data to the open-access World Health Organization (WHO) platform FluNet. These data include the number of specimens tested for influenza and the number of specimens positive for influenza by type, subtype and lineage, all by the epidemiologic week of specimen collection. We invited these laboratories to provide additional epidemiologic data about the hospitalized influenza B cases. We conducted descriptive analyses of patterns of influenza circulation and characteristics of hospitalized cases. We compared the predominant B lineage each season to the lineage in the vaccine applied, to determine vaccine mismatch. A Chi-square and Wilcoxan statistic were used to assess the statistical significance of differences in proportions and medians at the P<0.05 level.FindingsDuring 2010-2017, the annual number of influenza B cases in LAC was ~4500 to 7000 cases. Since 2011, among the LAC-laboratories reporting influenza B lineage using molecular methods, both B/Victoria and B/Yamagata were detected annually. Among the hospitalized influenza B cases, there were statistically significant differences observed between B/Victoria and B/Yamagata cases when comparing age and the proportion with underlying co-morbid conditions and with history of oseltamivir treatment (P<0.001). The proportion deceased among B/Victoria and B/Yamagata hospitalized cases did not differ significantly. When comparing the predominant influenza B lineage detected, as part of surveillance activities during 63 seasons among 19 countries, to the lineage of the influenza B virus included in the trivalent influenza vaccine used during that season, there was a vaccine mismatch noted during 32% of the seasons analyzed.ConclusionsInfluenza B is important in LAC with both B/Victoria and B/Yamagata circulating annually in all sub regions. During approximately one-third of the seasons, an influenza B vaccine mismatch was identified. Further analyses are needed to better characterize the medical and economic burden of each influenza B lineage, to examine the potential cross-protection of one vaccine lineage against the other circulating virus lineage, and to determine the potential impact and cost-effectiveness of using the quadrivalent vaccine rather than the trivalent influenza vaccine.

Project description:The financial implications of the increase in the prevalence of diabetes in middle-income countries represents one of the main challenges to health system financing and to the society as a whole. The objective of this study was to estimate the economic cost of diabetes in Latin America and the Caribbean (LAC) in 2015.The study used a prevalence-based approach to estimate the direct and indirect costs related to diabetes in 29 LAC countries in 2015. Direct costs included health care expenditures such as medications (insulin and oral hypoglycemic agents), tests, consultations, hospitalizations, emergency visits and treating complications. Two different scenarios (S1 and S2) were used to analyze direct cost. S1 assumed conservative estimates while S2 assumed broader coverage of medication and services. Indirect costs included lost resources due to premature mortality, temporary and permanent disabilities.In 2015 over 41 million adults (20 years of age and more) were estimated to have Diabetes Mellitus in LAC. The total indirect cost attributed to Diabetes was US$ 57.1 billion, of which US$ 27.5 billion was due to premature mortality, US$16.2 billion to permanent disability, and US$ 13.3 billion to temporary disability. The total direct cost was estimated between US$ 45 and US$ 66 billion, of which the highest estimated cost was due to treatment of complications (US$ 1?616 to US$ 26 billion). Other estimates indicated the cost of insulin between US$ 6 and US$ 11 billion; oral medication US$ 4 to US$ 6 billion; consultations between US$ 5 and US$ 6 billion; hospitalization US$ 10 billion; emergency visits US$ 1 billion; test and laboratory exams between US$ 1 and US$ 3 million. The total cost of diabetes in 2015 in LAC was estimated to be between US$ 102 and US$ 123 billion. On average, the annual cost of treating one case of diabetes mellitus (DM) in LAC was estimated between US$ 1088 and US$ 1818. Per capita National Health Expenditures averaged US$ 1061 in LAC.Diabetes represented a major economic burden to the countries of Latin America and the Caribbean in 2015. The estimates presented here are key information for decision-making that can be used in the formulation of policies and programs to achieve greater efficiency and effectiveness in the use of resources for diabetes prevention in the 29 countries of LAC.

Dataset Information

High-resolution gridded population datasets for Latin America and the Caribbean in 2010, 2015, and 2020.

Publications

High-resolution gridded population datasets for Latin America and the Caribbean in 2010, 2015, and 2020.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets